Zn-DDC to target hypoxia-NFkappaB-CSCs pathway in Multiple Myeloma
Research type
Research Study
Full title
Zn-DDC to target hypoxia-NFkappaB-CSCs pathway and improve the treatment outcomes of haematological malignancies – A Translation Bench Study
IRAS ID
278363
Contact name
Supratik Basu
Contact email
Sponsor organisation
The Royal Wolverhampton NHS Trust
Clinicaltrials.gov Identifier
n/a, n/a
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
The outlook for patients with haematological malignancies remains challenging. It has been shown in some early cancer studies that a particular drug called Zn-DDC otherwise known as Imuthiol is highly toxic to cancer stem cells. Imuthiol has been intravenously used in clinical trials with an excellent safety record.
Recent novel therapy and immunotherapy in haematological malignancies have improved outcome and survival but come with an increasing cost burden. Imuthiol could be an ideal affordable drug to study on it’s own as well as in combination with other drugs in myeloma and other haematological malignancies. This may lead to potential combination therapies which will be very effective as well as affordable in the future.
We need to look to see if this drug, Imuthiol and along with complementary drugs lenalidomide (Revlimid) and pomalidomide (Pomalyst) can help in haematological malignancy treatment. In order to do this we first have to see how the cancer cells respond to the drugs in the laboratory before being able to trial the drug (or combination of drugs) out for treatment.
The success of this study may lead to quick translation of Imuthiol into haematological malignancy treatment.
REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
20/WM/0041
Date of REC Opinion
31 Mar 2020
REC opinion
Favourable Opinion